SHILPAMED.NSE News

Costa Rica-based specialty healthcare company SteinCares has signed a licensing agreement with India’s Shilpa Biologicals, part of Shilpa Medicare, to commercialize a biosimilar across Latin America.

Shilpa Medicare Limited - 11/21/2025. Country: India. Record Type: 483

Indian pharmaceutical stocks, including Lupin, Shilpa Medicare, and Natco Pharma, are under scrutiny following recent USFDA inspections at their manufacturing sites. These audits yielded regulatory observations, prompting companies to address the findings. Alkem Laboratories, however, reported no critical issues from a separate Armenian health ministry audit at its Sikkim facility.

RAICHUR, India , Nov. 11, 2025 /PRNewswire/ -- Shilpa Pharma Lifesciences Limited, a material subsidiary of Shilpa Medicare Limited (BSE: 530549) (NSE: SHILPAMED), has been awarded the prestigious Gold Medal by EcoVadis , the world's most trusted provider of business sustainability ratings. The company achieved an exceptional score of 82/100 , placing it in the 98th percentile globally among 130,000 + companies evaluated by EcoVadis. This performance underscores our industry-leading Environmental, Social and Governance (ESG) practices and reflects our long-term commitment to building a responsible, resilient, and sustainable pharmaceutical enterprise. EcoVadis assesses organizations on four key pillars — Environment, Labor & Human Rights, Ethics, and Sustainable Procurement — and this recognition positions Shilpa Pharma Lifesciences among the top few global companies rated for sustainable business operations. Speaking on this milestone, Mr. Keshav Bhutada , ED & CEO of Shilpa Pharma Lifesciences emphasized that "Sustainability and innovation are integral to Shilpa's CDMO growth strategy to work with global innovator companies for their New chemical Entity programs.

Phase 3 study met all primary and secondary endpoints, demonstrating superior convenience, strong efficacy, and excellent safety versus conventional ondansetron injections RAICHUR, India , Nov. 11, 2025 /PRNewswire/ -- Shilpa Medicare Limited (BSE: 530549) (NSE: SHILPAMED) announced the successful completion of its fourth complex clinical program SMLINJ011 , with positive topline Phase 3 results for Shilpa's OERIS™ (Ondansetron Extended-Release Injection) —an innovative formulation designed to improve prophylaxis of chemotherapy-induced nausea and vomiting (CINV). This milestone underscores Shilpa's growing leadership in differentiated drug-delivery systems and oncology supportive-care therapeutics , reflecting the company's commitment to advancing patient-centric innovation. Study Overview A Phase III, multicenter, randomized, double-blind, non-inferiority trial was conducted across multiple oncology centers in India to compare OERIS™ with conventional ondansetron injections in 240 patients receiving moderately or highly emetogenic chemotherapy.

Raichur: KH Honneshaiah, head of operations at Shilpa Medicare, emphasised the importance of blood donation, stating that it has the potential to save.

IOC, Vodafone Idea, Glenmark Pharma, and AstraZeneca Pharma, among others, are expected to post their quarterly earnings today. JSW Cement to list at 10 am.

Sumeet Bagadia recommends five breakout stocks to buy today: Gujarat Apollo Industries, Vimta Labs, Skipper Ltd (India), Indian Metals and Ferro Alloys, and Shilpa Medicare.

Shilpa Medicare emerges as the global pioneer to receive approval for NorUDCA, offering new hope to over a billion people affected by Non-Alcoholic Fatty Liver Disease (NAFLD) NAFLD affects 1 in 4 people globally (1.2 billion), with 188 million patients in India—most undiagnosed until irreversible damage occurs. A Breakthrough in Liver Health: NorUDCA delivers a novel dual-action mechanism, combining anti-inflammatory benefits with enhanced bile acid regulation. This innovative therapy promises to halt the progression of NAFLD to severe liver conditions such as NASH, cirrhosis, and liver failure. Clinically Proven and Safe: Robust clinical trials demonstrate NorUDCA's significant superiority over placebo in efficacy, with an excellent safety profile and no major adverse events reported RAICHUR, India , Aug. 14, 2025 /PRNewswire/ -- In a landmark moment for global hepatology and Indian pharmaceutical innovation, Shilpa Medicare Limited (BSE: 530661) (NSE: SHILPAMED) has secured the world's first regulatory approval from India's Central Drugs Standard Control Organization (CDSCO) for Nor Ursodeoxycholic Acid (NorUDCA) Tablets 500 mg , the first-ever approved therapy targeting NAFLD.